A pre- and post-intervention study to assess the efficacy of tocilizumab in reducing mortality in hantavirus pulmonary syndrome
Hantavirus pulmonary syndrome
In this pre-post intervention study, all participants diagnosed with Hantavirus Pulmonary Syndrome (HPS) receive tocilizumab in addition to standard care. The study assesses the mortality rate before and after the intervention, comparing historical mortality data from patients with similar demographic and clinical profiles who did not receive tocilizumab. Tocilizumab is administered as a single intravenous dose of 8 mg/kg, up to a maximum of 800 mg, within the first 24 hours of hospital admission. The primary outcome measure is the mortality rate at 28 days post-intervention. The study is conducted in a hospital setting, ensuring that all participants are monitored for safety and efficacy outcomes.
1. Diagnosis confirmation: participants must be clinically diagnosed with Hantavirus Pulmonary Syndrome. Diagnosis should be confirmed through one or more of the following: 1.1. Detection of hantavirus-specific IgM antibodies in serum. 1.2. A four-fold rise in hantavirus-specific IgG antibody titers in paired serum samples. 1.3. Positive RT-PCR test for hantavirus RNA in blood or tissue samples. 2. Age: participants must be aged 18 years or older. This age criterion ensures that all participants can legally consent to the study and are within the adult age range most commonly affected by HPS. 3. Severity of condition: participants must be exhibiting symptoms severe enough to require hospitalization, ensuring the study targets those most likely to benefit from tocilizumab treatment. 4. Ability to provide informed consent: participants must be capable of giving informed consent or have a legal guardian who can consent on their behalf if they are incapacitated. 5. Treatment window: participants must be eligible to receive the study intervention (tocilizumab) within 24 hours of hospital admission to ensure the treatment is administered in a timely manner, which is critical for its potential efficacy. 6. Health status: participants must have no known allergies to tocilizumab or its excipients. 7. No severe co-morbid conditions that could interfere with the study outcomes or significantly increase the risk of adverse effects from tocilizumab, such as severe chronic liver disease, known active tuberculosis, or other severe active infections. 8. No prior treatment: participants must not have received tocilizumab or other investigational treatments for HPS before enrollment in this study to ensure that any observed effects can be attributed to the study drug.
1. Previous treatment with tocilizumab or related therapies: participants who have previously received tocilizumab or other monoclonal antibodies targeting IL-6 or IL-6 receptors for any condition. 2. Severe allergic reactions: individuals with a history of severe allergic reactions to tocilizumab or any of its excipients. 3. Active or latent infections: participants with active, severe infections at the time of screening, such as tuberculosis, HIV, or hepatitis. 4. Individuals with a known history of chronic or recurrent infections. 5. Pregnancy or lactation: pregnant or breastfeeding women due to the unknown effects of tocilizumab on fetuses or infants. 6. Severe comorbid conditions: individuals with uncontrolled cardiovascular, liver, renal, or metabolic diseases that could complicate treatment outcomes. 7. Patients with a known history of gastrointestinal perforation within the last 6 months. 8. Recent vaccinations: participants who have received live vaccines within 30 days prior to the intended start of treatment. 9. Participation in other clinical trials: individuals currently participating in another clinical trial or who have participated in a clinical trial involving an investigational product within the last 30 days. 10. Substance abuse: current or recent (within the last year) history of significant alcohol or drug abuse that could interfere with adherence to study protocols. 11. Immunosuppression: patients with conditions or on treatments that significantly suppress immune function, such as chemotherapy or high-dose corticosteroids. 12. Psychiatric illness: individuals with psychiatric illnesses or conditions that could interfere with their ability to understand or comply with the requirements of the study.